Researchers investigate how oxygen radicals protect against cancer
Originally, oxygen radicals - reactive oxygen species, or ROS for short - were considered to be exclusively harmful in the body.
They are produced, for example, by smoking or UV radiation. Because of their high reactivity, they can damage many important molecules in cells, including the hereditary molecule DNA. As a result, there is a risk of inflammatory reactions and the degeneration of affected cells into cancer cells.
Because of their damaging effect, however, ROS are also deliberately produced by the body, for example by immune or lung epithelial cells, which destroy invading bacteria and viruses with ROS. This requires relatively high ROS concentrations.
PerkinElmer supports PROXIDRUGS consortium to address disease-relevant human proteins
PerkinElmer supports PROXIDRUGS consortium to address disease-relevant human proteins 26 April 2021 | News
Photo Credit: Freepik
PerkinElmer, Inc., announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras).
PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics.
The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells’ natural shr
How oxygen radicals protect against cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
PerkinElmer, Inc.: PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs
Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology
Science’s COVID-19 reporting is supported by the Heising-Simons Foundation.
Researchers in Germany and Canada have added provocative new details to their proposal for how the COVID-19 vaccine made by AstraZeneca might be causing an unusual clotting disorder in a small number of recipients. The mechanism, involving stray human proteins and a preservative in the vaccine, remains speculative. And it is not clear whether their hypothesis explains similar reactions observed in recipients of the COVID-19 vaccine made by Johnson & Johnson (J&J).
The new data are “interesting but not a smoking gun by any means” for the group’s hypothesis, says Gowthami Arepally, a hematologist at the Duke University School of Medicine who is working as an external consultant with AstraZeneca on the issue. But figuring out what in a COVID-19 vaccine might start the sometimes fatal combination of blood clotting and low platelets is crucial for developing better treatments for the side effect and po